

FOGHORN[®]

THERAPEUTICS

Unique biology

Precision therapeutics

Broad impact

December 2024

Forward Looking Statements

This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "could," "may," "might," "will," "likely," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects," "continues," "projects" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning: the potential outcomes from our collaboration agreement with Lilly; the initiation, timing, progress and results of our research and development programs and pre-clinical studies and clinical trials, including with respect to our Phase 1 dose escalation trial of FHD-909 with Lilly; our ability to advance product candidates that we may develop and to successfully complete preclinical and clinical studies; our ability to leverage our initial programs to develop additional product candidates using our Gene Traffic Control Platform®; the impact of exogenous factors, including macroeconomic and geopolitical circumstances, on our and our collaborators' business operations, including our research and development programs and pre-clinical studies; developments related to our competitors and our industry; our ability to expand the target populations of our programs and the availability of patients for clinical testing; our ability to obtain regulatory approval for FHD-909 and any future product candidates from the FDA and other regulatory authorities; our ability to identify and enter into future license agreements and collaborations; our ability to continue to rely on our CDMOs and CROs for our manufacturing and research needs; regulatory developments in the United States and foreign countries; our ability to attract and retain key scientific and management personnel; the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering FHD-909, our future products and our Gene Traffic Control Platform; and our use of proceeds from capital-raising transactions, estimates of our expenses, capital requirements, and needs for additional financing. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation. Additional important factors to be considered in connection with forward-looking statements are described in the Company's filings with the Securities and Exchange Commission, including within the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Any forward-looking statements represent the Company's views only as of the date of this presentation and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements. The Company's business is subject to substantial risks and uncertainties.

Foghorn is the Pioneer in Chromatin Biology, an Untapped Area for Therapeutics


What if ... It were possible to **develop a therapeutic approach to treat half of all cancers?**

Chromatin biology is implicated in up to 50% of tumors

~2.5 million cancer patients

Potential for therapeutic area expansion (e.g., I&I)

Chromatin Regulatory System Orchestrates Gene Expression; Multiple Opportunities for Targets and Therapeutics



Foghorn has Progressed Multiple Programs Against Challenging Targets

SMARCA2: Potential in up to 5% of all solid tumors
Challenge: Industry has failed to develop a selective inhibitor

FHD-909
first selective inhibitor in the clinic

CBP: Role in bladder, colorectal, breast, gastric, lung cancers
Challenge: Toxicities with dual inhibition, difficulty engineering selectivity

Selective CBP Degradator
IND enabling studies anticipated by end of year


EP300: Role in both solid and heme malignancies
Challenge: Toxicities with dual inhibition, difficulty engineering selectivity

Selective EP300 Degradator
IND enabling studies anticipated in 2025

ARID1B: Role in ovarian, endometrial, colorectal cancer
Challenge: Industry has had no success with selective target engagement

Selective ARID1B binder identified. Critical step towards degradation

Foghorn's Gene Traffic Control® Platform Designed to Deliver Precision, First-in-Class Therapeutics: Integrated, Scalable, Efficient, Repeatable




Foghorn's Unique Platform Capabilities Evolved from Drugging a Specific Chromatin Remodeling Complex (BAF)*

Challenge: produce, manipulate, study, and drug a 1.5 megadalton multi-protein complex

Assays and Biochemistry Capabilities

- Purification & recombinant production of large proteins and protein complexes
- Biochemistry & biophysics of intrinsically disordered proteins
- High throughput screening for binders and inhibitors

BAF Chromatin Remodeling Complex



Challenge: drug highly similar proteins that have no enzymatic function

Protein Degradation Platform

- Proprietary linker library
- Suite of assays specific to degradation (i.e., synthesis kinetics, degradation kinetics)
- Optimal E3 ligase pairing
- Ternary complex modeling
- Long-acting formulation technology


Current and Future Applications

- Selectively drugging highly similar proteins / hard to drug proteins
- Disease area expansion
- Going beyond chromatin – novel biology with complex proteins
- Payloads for ADCs*

*Brahma-Associated Factor (BAF). Antibody Drug Conjugates (ADCs).


The Next Foghorn Chapter: Delivering Multiple Potential Blockbusters into the Clinic

Pioneering BAF and Chromatin Biology (2016 – 2020)




- ✓ Built platform and developed deep understanding of biology
- ✓ Producing BAF and transcription factors at scale
- ✓ **Demonstrated druggability of chromatin regulatory system**

POC, Platform & Pipeline Expansion (2021 – 2024)



Differentiation



- ✓ **Lilly strategic collaboration**
- ✓ Initiated efforts on CBP and EP300
- ✓ FHD-286 demonstrated mutation-agnostic differentiation effect in acute myeloid leukemia (AML)
- ✓ Expansion of protein degrader platform

Progress Multiple High Value Assets into the Clinic (2025 – 2027)




- **Proof of concept data for SMARCA2 Selective Inhibition (FHD-909) in NSCLC***
- **Potential for 5 additional INDs**
- **Pipeline, platform, disease area expansion**

*Non-small cell lung cancer (NSCLC)



Foghorn Is Advancing a Pipeline of First-in-Class Precision Therapeutics with Potential for Broad Application in Oncology...



*LY4050784
SMARCA2 = BRM

...with Multiple Near-Term Value Inflection Points through 2026



SMARCA2 = BRM
SMARCA4 = BRG1

Potential Multi-Billion Dollar Opportunities in Oncology



Foghorn Owned

Partnered w Lilly

Potential for therapeutic area expansion
(e.g., immunology and inflammation)

Clinical & Pre-Clinical Programs

- FHD-909 (LY4050784) – Selective SMARCA2 Inhibitor
- Selective CBP Degradar
- Selective EP300 Degradar
- Selective ARID1B Program



Selective SMARCA2 Modulators

For SMARCA4 Mutated Cancers


SMARCA2 = BRM
SMARCA4 = BRG1

FHD-909, SMARCA2 Selective Inhibitor in Phase 1 Trial; Selective SMARCA2 Degradar Continues Late-Stage Pre-Clinical Development

	SMARCA2 Selective Inhibitor (FHD-909*)	SMARCA2 Selective Degradar
Biology	Exploit the synthetic lethal relationship between SMARCA2 and mutated SMARCA4	
Stage	Phase 1 dose escalation trial	Advancing in parallel through late pre-clinical development
Opportunity	SMARCA4 mutated cancer including ~10% of NSCLC and up to 5% of all solid tumors	
Lilly Partnership	50/50 global R&D cost share 50/50 U.S. economics tiered ex-U.S. royalties starting in the low double-digit range and escalating into the twenties	


*LY4050784

Selective SMARCA2 Inhibition: Promising Strategy to Exploit Synthetic Lethal Relationship Between SMARCA2 and Mutant SMARCA4



Precision medicine targeting synthetic lethal relationships is a proven clinical approach now used in multiple cancers (e.g., PARP inhibitors)

SMARCA4 is Mutated in Up to 10% of NSCLC; Up to 5% of Solid Tumors




SMARCA4 mutated across a broad range of tumors


Accounts for ~5% of solid tumors

Patients with NSCLC Harboring SMARCA4 Mutations Have Significantly Worse Clinical Outcomes and Define a High Unmet Need Patient Population


Overall Survival for SMARCA4wt vs SMARCA4mut¹



SMARCA4 mutated in up to 10% of NSCLC tumors, minimal overlap with other mutations²



FHD-909 Demonstrated Approximately 33-fold Selectivity Across 17 SMARCA4 Mutant and Wild-Type Cell Lines *In Vivo*




Spread in potency for wild type versus mutant cell lines indicates


33-fold selectivity observed

FHD-909 Monotherapy Demonstrated Regression *In Vivo* in H2126 SMARCA4 Mutant NSCLC Model and Was Well Tolerated

H2126 Reduction in Tumor Volume



H2126 Body Weight




Genetic Background: SMARCA4 W764R, TP53 E62*, STK11-/-, CDKN2A-/-, KEAP1 R272C

NOTE: All doses were well tolerated. Dosing holidays were applied at the high dose, as appropriate.


FHD-909 Monotherapy Demonstrated 96% TGI in A549 and Tumor Stasis in RERF-LC-AI Mutant NSCLC Models

A549 Model



Genetic Background | *SMARCA4, Q729fs / H736Y, KRAS G12S, STK11-/-, CDKN2A-/-, KEAP1 G333C*

RERF-LC-AI Model




Genetic Background | *SMARCA4 mut p.E1496*, TP53 p.Q104*, NF1 p.E1699**

NOTE: All doses were well tolerated. Dosing holidays were applied at the high dose, as appropriate.

FHD-909 Monotherapy Demonstrated Regression in H1793 SMARCA4 Mutant NSCLC Model

H1793 Model



- **FHD-909** delivered across range of SMARCA4 mut xenograft models
- Results ranging from impressive TGI to regression as monotherapy
- All doses across all four models were well tolerated

Genetic Background | SMARCA4, E514*, TP53 R209* R273H, ARID1A C884*

NOTE: All doses were well tolerated. Dosing holidays were applied at the high dose, as appropriate

FHD-909 Trial Design



Dose Escalation

- Restricted to SMARCA4 mutated tumors
- SMARCA4 mutant status confirmed by standard NGS panel
- Further enrichment for NSCLC patients as trial progresses
- Tumor histology agnostic

Dose Expansion


- Arm 1: SMARCA4 mutant NSCLC
- Arm 2: Other SMARCA4 mutant tumors (e.g., bladder, endometrial, colorectal)
- Potential for combination arm(s)

SMARCA2 Selective Degradator Achieved Complete SMARCA2 Degradation and Cell Growth Inhibition *In Vitro*



Degraders Caused Time- and Dose-Dependent SMARCA2 Degradation
Antiproliferative Effects in A549 Mutant NSCLC Model

CBP and EP300 Proteins – A Decades Long Challenge in Selectivity



- **CBP** and **EP300** are chromatin regulators and histone acetyltransferases
- **CBP** and **EP300** are virtually identical, thus achieving selectivity is a significant challenge
 - Dual targeting has revealed tolerability and safety issues

Foghorn is working on two separate programs, each with their own defined dependencies and patient populations




Selective CBP Protein Degradator

For EP300 Mutated Cancers




Summary: Selective CBP Protein Degradator for EP300 Mutated Cancers

Target / Approach	<ul style="list-style-type: none"> • CREB binding protein (CBP) • Targeted protein degrader
Initial Indication	<ul style="list-style-type: none"> • EP300 mutated cancers (e.g., subsets of bladder, colorectal, breast, gastric and lung cancers)
Mutation / Aberration	<ul style="list-style-type: none"> • EP300 mutated cancers
Stage	<ul style="list-style-type: none"> • Pre-clinical
New Patients Impacted / Year*	<ul style="list-style-type: none"> • Over 100,000





* Per year incidence in the U.S., EU5, Japan . Source: Clarivate DRG Mature Markets Data.

Selective CBP Degradation Resulted in Significant Tumor Growth Inhibition in Colorectal & Bladder and Regression in Gastric EP300 Null Models




Pre-Clinical Studies Indicate Selective CBP Degradation Did Not Show Thrombocytopenia and Spares Megakaryocytes *In Vivo*




Pre-Clinical Studies Indicate Long-Acting Injectable Formulations of CBP Degradar Could Enable At Least Once Every 2 Weeks Dosing


dCBP-9 PK/PD (60mg/kg, sc)



dCBP-9 PK/PD (150mg/kg, sc)



dCBP-9 PK/PD (150mg/kg, im)






Selective EP300 Protein Degradator

For CBP Mutated and EP300 Dependent Cancers



Summary: Selective EP300 Protein Degradator for CBP Mutant & EP300 Dependent Cancers

Target / Approach	<ul style="list-style-type: none"> E1A binding protein p300 (EP300) Targeted protein degrader
Initial Indications	<ul style="list-style-type: none"> AR+ Prostate DLBCL Bladder, melanoma, others
Mutation / Aberration	<ul style="list-style-type: none"> EP300 dependent cancers CBP mutant cancers
Stage	<ul style="list-style-type: none"> Pre-clinical
New Patients Impacted / Year*	<ul style="list-style-type: none"> Over 100,000




* Per year incidence in the U.S., EU5, Japan. Source: Clarivate DRG Mature Markets Data.

EP300 Degradation Results in Significant Tumor Growth Inhibition in AR+ VCAP Prostate and KARPAS422 DLBCL Models



Selective EP300 Degradation Does Not Show Thrombocytopenia *In Vivo*





Selective ARID1B Protein Degradator

For ARID1A Mutated Cancers



ARID1B is a Major Synthetic Lethal Target Implicated in Up To 5% of All Solid Tumors

Target / Approach

- ARID1B
- Targeted protein degrader

Initial Indication

- ARID1A mutated cancers

Mutation / Aberration



- ARID1A mutations (e.g., ovarian, endometrial, colorectal, bladder and other cancers)

Stage


- Pre-clinical

New Patients Impacted / Year*

- > 175,000



Commercial Opportunity




~5% of all solid tumors harbor ARID1A mutations

* Per year incidence in the U.S., EU5, Japan. Source: Clarivate DRG Mature Markets Data.


Compound Screening and Structure-Based Optimization Yielded Selective ARID1B Binders

Identification of Selective ARID1B Binders



- Mapped and purified several potential ligandable regions of ARID, which were then screened against various compound libraries
- Characterized binding using multiple biochemical and biophysical techniques: e.g., DSF, ASMS, NMR, and SPR

X-Ray Crystal Structures Detail Selective ARID1B Binding





- Determined X-ray crystal structure of ARID ligandable domains with specific binders
- Leveraged these structures to drive binding affinities and expand binding chemotypes

Structure-Based Optimization Drove Improved ARID1B Binding Affinity from 100 μM to less than 200 nM

Gen 1: Screening Hit



ARIDb-1
ARID1B Kd: **100 μM**



1.4 Å co-xtal structure

Gen 2: Early Optimization



ARIDb-2
ARID1B Kd: **15 μM**



2.0 Å soak structure



Gen 3: Sub- μM Affinity

ARIDb-3
ARID1B Kd: **0.5 μM**



1.9 Å co-xtal structure

ARIDb-9
ARID1B Kd: **0.2 μM**



1.7 Å soak structure

... with Multiple Near-Term Value Inflection Points through 2026



SMARCA2 = BRM
SMARCA4 = BRG1

Developing First-In-Class Precision Medicines Targeting Major Unmet Needs in Cancer



Leader in Unique Area of Cancer Biology

Foghorn is a **leader in targeting chromatin biology**, which has the potential to address underlying dependencies of many genetically defined cancers

Platform with initial focus in oncology, **therapeutic area expansion potential**



Large Market Potential

Chromatin biology is implicated in up to **50% of tumors**, potentially impacting **~2.5 million patients**

Foghorn's current pipeline potentially addresses **more than 500,000** of these patients

Broad pipeline across a range of targets and small molecule modalities



Well-Funded

\$267.4 million in cash and equivalents
(as of 9/30/2024)

Cash runway into 2027

Shares outstanding: approximately 62.5M*



Value Drivers

SMARCA2 Selective Inhibitor (FHD-909), partnered with Lilly, in **Phase 1 trial**

Advancement of preclinical assets (SMARCA2 Selective Degradar, CBP, EP300, ARID1B) towards INDs



Major Strategic Collaboration

Strategic collaboration with Lilly; **\$380 million upfront**; 50/50 U.S. economic split on two lead programs

*Includes common shares outstanding as of 6/30/2024 as well as common stock and pre-funded warrants issued as part of May 2024 financing



FOGHORN[®]

THERAPEUTICS

The background of the slide features a stylized, light blue DNA double helix that winds across the frame. Scattered around the helix are numerous small, interconnected nodes and lines, resembling a molecular or network structure. The Foghorn Therapeutics logo is centered in the upper half of the slide, with the word 'FOGHORN' in a large, bold, blue sans-serif font and 'THERAPEUTICS' in a smaller, bold, blue sans-serif font below it. A thin green horizontal line is positioned below the logo.

Unique biology

Precision therapeutics

Broad impact

December 2024

40 |



Appendix



Lilly Collaboration Validates Foghorn Approach: Significant Upfront and Deal Economics



\$380 Million Up-front

\$300 million cash

\$80 million in Foghorn common stock at a price of \$20 per share



50/50 U.S. Economics on Two Programs

50/50 U.S. economic split on SMARCA2-Selective and another undisclosed program

Tiered ex-U.S. royalties starting in the low double-digit range and escalating into the twenties based on revenue levels



Three Undisclosed Discovery Programs

Option to participate in a percentage of the U.S. economics

Tiered ex-U.S. royalties from the mid-single digit to low-double digit range

\$1.3 billion in potential milestones





Transcription Factors

A Novel Approach

HD 405 (R)

Protein

Protein

Protein



Foghorn's Novel Approach to Drugging Transcription Factors Enabled by Its Protein Production and Discovery Capabilities

Transcription Factors are Compelling Drug Targets...


- Highly involved in gene expression
- Implicated in range of cancers and other diseases

...But Historically Difficult to Target...



- Featureless surface: no druggable binding pocket
- Tight interactions with DNA: undruggable affinities

Foghorn Has a New Approach Focusing on Interaction with BAF

- Druggable binding pockets
- Druggable affinities




Transcription Factors Bind to BAF Directly with Specificity; Unique Insights into Where and How Transcription Factors Bind




Mapping the TF-BAF Interaction

Mass spec. foot-printing



Pull-down assays




Foghorn's collection of BAF sub-complexes and domains

Validating the TF-BAF Interaction

Biophysical

AUC / SPR / ITC



Biochemical

TR-FRET / FP



Structural

Crystal / NMR

